Pelthos Therapeutics Inc.
PTHS
$26.90
$0.602.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 858.25% | 617.89% | 493.01% | 3,860.00% | -58.42% |
| Gross Profit | 4,763.40% | 2,676.49% | 1,291.57% | -3,860.00% | 58.42% |
| SG&A Expenses | 1,186.83% | 1,100.06% | 1,101.22% | 55.08% | 11.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,208.29% | 1,072.81% | 1,011.18% | 83.12% | -5.17% |
| Operating Income | -613.63% | -558.06% | -649.73% | -83.12% | 5.17% |
| Income Before Tax | -420.22% | -1,384.22% | -885.43% | -94.68% | 23.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -420.22% | -1,024.82% | -857.99% | -94.68% | 23.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -420.22% | -1,024.82% | -857.99% | -94.68% | 23.19% |
| EBIT | -613.63% | -558.06% | -649.73% | -83.12% | 5.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 3.72% | -115.26% | -81.25% | -75.49% | 41.21% |
| Normalized Basic EPS | 3.73% | -181.20% | -86.45% | -75.48% | 41.21% |
| EPS Diluted | 3.72% | -115.26% | -81.25% | -75.49% | 41.21% |
| Normalized Diluted EPS | 3.73% | -181.20% | -86.45% | -75.48% | 41.21% |
| Average Basic Shares Outstanding | 440.33% | 422.53% | 428.57% | 10.93% | 30.65% |
| Average Diluted Shares Outstanding | 440.33% | 422.53% | 428.57% | 10.93% | 30.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |